Library

Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.

1 June 2013. doid: 10.1111/bcp.12015

Liem-Moolenaar M, Peeters P, Kamerling IM, Hogg C, Holder G, Kleijn HJ, Spaans E, Udo De Haes J, de Kam ML, Franson KL, Cohen AF, van Gerven JM

View publication

To report the first three studies with SCH 900435, a selective glycine-1 re-uptake inhibitor in development for treating schizophrenia, using systematic evaluations of pharmacodynamics to understand the observed effects.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact